AGENDA
Health Canada International Symposium on Drug, Food and Natural Health Product Interactions
Chaudière Room, Château Cartier Resort
1170 Aylmer Road, Gatineau, Québec
February 9 - 10, 2006
Purpose
The purpose of the two-day Symposium is to increase awareness of drug, food and natural health product (NHP) interactions and to assist Health Canada in further developing risk management strategies related to the health effects of these interactions.
Thursday, February 9, 2006
Introduction
| 07:30 - 08:30 |
Registration and Continental breakfast |
| 08:30 - 08:40 |
Greetings from the Co-chairs
Dr. Brian Foster
Therapeutic Products Directorate, Health Canada, Ottawa.
See profile
Dr. Edzard Ernst
Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, United Kingdom.
See profile |
| 08:40 - 09:00 |
Opening Remarks
Mr. Omer Boudreau, Director General
Therapeutic Products Directorate, Health Canada, Ottawa, Canada.
Mr. Neil Yeates, Assistant Deputy Minister
Health Products and Food Branch, Health Canada, Ottawa, Canada.
|
Symposium
| 09:00 - 12:00 |
Session 1
Reason for Concern: Adverse Effects due to Interactions between Drugs, Foods and Natural Health Products
Session 1 aims to address the issue that drugs, foods and natural health products can each have a beneficial health effect and yet, if used together, may result in interactions causing adverse health events. The speakers will provide an overview of these phenomena, including the possible severity of adverse effects, their potential prevalence, and an examination of some of the factors that may influence their occurrence.
Session 1 Co-Chairs:
Dr. Joel Rotstein Bureau of Chemical Safety, Food Directorate, Health Canada, Ottawa, Canada.
See profile
Dr. Edzard Ernst Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, United Kingdom.
See profile
Session 1 Speakers: |
| 09:00 - 10:00 |
Interactions - an Overview. Dr. Edzard Ernst, Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, United Kingdom.
See abstract
|
| 10:00 - 10:30 |
Break |
| 10:30 - 11:15 |
Herb-Drug Interactions: Issues and Perspectives. Mr. Mark Blumenthal, American Botanical Council, Austin, Texas, USA.
See profile
See abstract
|
| 11:15 - 12:00 |
Risk of Drug Interactions Involving Herbal and Citrus Products.
Dr. Shiew-Mei Huang, United States Food and Drug Administration, Washington, DC, USA.
See profile
|
| 12:00 -13:00 |
Lunch provided by Health Canada |
| 13:00 -16:30 |
Session 2
Mechanisms of Action: How Interactions between Drugs, Foods and Natural Health Products Happen
Session 2 aims to highlight our present understanding of the mechanisms underlying adverse interactions between drugs, foods and natural health products. The talks will discuss various modes of action including issues such as absorption, disposition and metabolism. In addition, the role of culture and genetic variations in these adverse events will be presented. A central question in this session will be: how we can use the data to help avoid interactions?
Session 2 Co-Chairs:
Dr. Valerie Assinewe Natural Health Products Directorate, Health Canada, Ottawa, Canada.
See profile
Dr. David Bailey London Health Sciences Centre and University of Western Ontario, London, Ontario, Canada.
See profile
|
| 13:00 - 14:00 |
Current Understanding of Mechanisms and Clinical Relevance of Food-Drug Interactions: From Inactivation of Drug Metabolism to Inhibition of Drug Transport. Dr. David Bailey, London Health Sciences Centre and University of Western Ontario, London, Ontario, Canada.
See abstract
|
| 14:00 - 14:40 |
Molecular Basis of Herbal-Drug Interactions. Dr. Richard Kim, Vanderbilt University School of Medicine, Nashville, TN, USA.
See profile
See abstract
|
| 14:40 - 15:10 |
Break |
| 15:10 - 15:50 |
Drug Interactions with St. John's Wort: Clinical Evidence. Dr. Angelo A. Izzo, Federico II University of Naples, Naples, Italy.
See profile
See abstract
|
| 15:50 - 16:30 |
Future Focus for Herb-Drug Interaction Studies: Predict, Prepare, and Prevent. Dr. Shufeng Zhou, National University of Singapore, Republic of Singapore.
See profile
See abstract
|
| 16:30 - 17:00 |
Wrap-up Day 1 |
| 17:00 |
Adjourn Day 1 |
Friday, February 10, 2006
| 07:30 - 08:30 |
Registration and Continental breakfast |
| 08:30 - 08:45 |
Greetings from the Co-chairs
Review of Day 2 Agenda
Dr. Brian Foster
Therapeutic Products Directorate, Health Canada, Ottawa.
See profile
Dr. Edzard Ernst
Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, United Kingdom.
See profile |
| 08:45 - 12:00 |
Session 3
International Post-Market Surveillance: Monitoring, communicating, and mitigating the risk
Session 3 aims to discuss effective surveillance and risk communication strategies concerning drug, food and Natural Health Product interactions. Regulators and researchers in the area of pharmacovigilance and risk communication will share their recommendations and expertise from an international perspective.
Session 3 Co-Chairs:
Dr. Jenna Griffiths Marketed Health Products Directorate, Health Canada, Ottawa, Canada.
See profile
Dr. Joanne Barnes Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
See profile
Session 3 Speakers: |
| 08:45 - 09:00 |
Risk Management Strategies: Challenges and Opportunities Specific to Natural Health Products. Dr. Jenna Griffiths, Marketed Health Products Directorate, Health Canada.
See profile
|
| 09:00 - 09:45 |
Interactions between Herbal Medicinal Products, "Natural Health" Products and Other Medicines: Pharmacovigilance Strategies in the United Kingdom and New Zealand. Dr. Joanne Barnes, School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand,
See abstract
|
| 09:45 - 10:20 |
The Role of the Uppsala Monitoring Centre in Safety Monitoring of Herbal Medicines. Dr. Mohamed H. Farah, WHO Uppsala Monitoring Centre, Uppsala, Sweden.
See profile
See abstract
|
| 10:20 - 10:40 |
Break |
| 10:40 - 11:10 |
Clinical Risk Management of Herb-Drug Interactions. Dr. Peter AGM de Smet, Scientific Institute of Dutch Pharmacists, University Medical Center, The Netherlands.
See profile
See abstract
|
| 11:10 - 11:45 |
The control of Traditional Medicine and the Risk Communication Strategies of the Health Sciences Authority, Singapore. Dr. Cheng Leng Chan, Health Sciences Authority, Republic of Singapore.
See profile
See abstract
|
| 11:45 - 12:20 |
Warfarin-herb Interactions: Fact, Fiction and Pharma Influence. Dr. Adriane Fugh-Berman, Georgetown University School of Medicine, Washington, DC, USA.
See profile
See abstract
|
| 12:20 - 12:30 |
Session 3 Wrap-up: Dr. Joanne Barnes
See profile
|
| 12:30 - 14:00 |
Lunch and Poster Presentations |
| 14:00 - 16:30 |
Session 4
How to better assist consumers avoid adverse events due to interactions among drugs, foods and natural health products?
Session 4 - Participants will hear from panel members and stakeholders on how to avoid interactions among drugs, foods and Natural Health Products.
Preliminary questions to consider may include:
- What information is required for the consumer to make an informed decision?
- How should this information be conveyed to the consumer and by whom?
- What are the responsibilities of regulatory bodies, industry and the consumer in mitigating the risk of interactions?
Session 4 Chair:
Mr. Mark Blumenthal American Botanical Council, Austin, Texas, USA.
See profile
Session 4 Panel members:
Mr. Ron Rosenes Canadian Treatment Action Council, Toronto, Canada.
See profile
Dr. Paul Saunders Canadian College of Naturopathic Medicine, Toronto, Canada.
See profile
Dr. Sunita Vohra Faculty of Medicine, University of Alberta, Edmonton, Canada.
See profile
|
| 16:30 - 16:45 |
Session 4 Wrap-up: Mr. Mark Blumenthal
See profile
|
| 16:45 - 17:00 |
CLOSING
Closing remarks |
| 17:00 |
Adjourn |
|
